Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.

× No keyword cloud information.

10 in total

1. Sorafenib Induced Hand-Foot Skin Reaction at Low Dose.

Authors: Vrutika H Shah; Bhagyashree B Supekar; Rajesh P Singh; Jayesh I Mukhi
Journal: Indian Dermatol Online J Date: 2020-09-19

Review 2. Myelodysplasia and malignancy-associated vasculitis.

Authors: Amir Agha; Helen Bateman; Ashley Sterrett; Joanne Valeriano-Marcet
Journal: Curr Rheumatol Rep Date: 2012-12 Impact factor: 4.592

3. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.

Authors: Emmanuelle Faye; Emmanuelle Bondon-Guitton; Pascale Olivier-Abbal; Jean-Louis Montastruc
Journal: Eur J Clin Pharmacol Date: 2013-06-09 Impact factor: 2.953

Review 4. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

Authors: Rebecca L Stone; Anil K Sood; Robert L Coleman
Journal: Lancet Oncol Date: 2010-03-10 Impact factor: 41.316

5. Array of cutaneous adverse effects associated with sorafenib.

Authors: Heidi H Kong; Maria L Turner
Journal: J Am Acad Dermatol Date: 2009-08 Impact factor: 11.527

6. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

Authors: Nilofer S Azad; Jeanny B Aragon-Ching; William L Dahut; Martin Gutierrez; William D Figg; Lokesh Jain; Seth M Steinberg; Maria L Turner; Elise C Kohn; Heidi H Kong
Journal: Clin Cancer Res Date: 2009-02-15 Impact factor: 12.531

Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib.

1. Sorafenib Induced Hand-Foot Skin Reaction at Low Dose.

Review 2. Myelodysplasia and malignancy-associated vasculitis.

3. Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitors.

Review 4. Collateral damage: toxic effects of targeted antiangiogenic therapies in ovarian cancer.

5. Array of cutaneous adverse effects associated with sorafenib.

6. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-vascular endothelial growth factor therapy.

7. Sorafenib-associated facial acneiform eruption.

8. Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist.

9. Sorafenib metabolism is significantly altered in the liver tumor tissue of hepatocellular carcinoma patient.

10. The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.